VCYT Stock Price Today (October 2026) — Veracyte, Inc. Analysis & Key Metrics 2026-10-07
Veracyte, Inc. (VCYT) is trading at $43.16, down 3.34% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $58.42 (35.4% upside).
- Volatility is high (62.22% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (15.50% YoY) alongside competitive pressures in the Diagnostics & Research space.
VCYT Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Veracyte, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $3.02B
P/E Ratio
Forward P/E: 22.17
Revenue Growth
Year over Year
Analyst Target
+35.4% upside potential
Key Investor Questions About VCYT
What investors need to know before buying
Based on current market data, VCYT presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 46.15)
- Fundamentals say: Looking solid (debt and growth supportive)
VCYT's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for VCYT investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $40.11M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, VCYT stock traded between $29.46 and $60.91 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 62.22% annualized volatility and β=1.44, the stock exhibits high sensitivity to market moves—making VCYT suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?
Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.
Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies
Veracyte, Globus Medical and UFP Technologies are positioned to benefit as GenAI adoption reshapes medical instruments.
Is it Worth Adding Veracyte Stock to Your Portfolio Now?
VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround
Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Veracyte Q2 Earnings Call Highlights
Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD recurrence-monitoring test for muscle-invasive bladder cancer. Chief Executive Officer Marc Stapley
Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?
Veracyte (VCYT) is back in focus after raising its 2026 revenue guidance to a range of US$590 million to US$596 million, and releasing detailed second quarter and first half earnings results. See our latest analysis for Veracyte. The earnings beat and higher 2026 revenue guidance have coincided with strong momentum in Veracyte’s stock. The latest share price of US$59.78 reflects a 90 day share price return of 80.66%, while the 1 year total shareholder return is 152.88%. If Veracyte’s results...
Veracyte Inc (VCYT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Launches ...
Veracyte Inc (VCYT) raises full-year guidance after delivering 15% revenue growth and launching Prosigna and TrueMRD, positioning for long-term expansion.
Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of +25.58% and +4.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Explore More Analysis for VCYT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 2, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Veracyte, Inc.
Veracyte, Inc. (VCYT) is currently trading at $43.16. The RSI (14-day) is at 46.2, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $58.42 implies 35.4% upside from current levels. Volatility is high at 62.2% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Veracyte, Inc. (VCYT): The trailing P/E ratio is 29.44, which is in line with broader market averages. The forward P/E is 22.17, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 2.39. Price-to-Sales is 5.90. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering VCYT, the consensus price target is $58.42. This represents a 35.4% upside from the current price of $43.16. The range spans from a low target of $44.00 to a high target of $70.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Veracyte, Inc. (VCYT) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Veracyte, Inc. (VCYT) investors include: 1. High volatility (62.2% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (12.3% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Veracyte, Inc.'s (VCYT) current debt and financial health profile: Total debt stands at $40.11M. The debt-to-equity ratio is 0.03x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 9.16, indicating strong short-term liquidity. The quick ratio is 8.60. The company holds $485.23M in cash and equivalents. Free cash flow is positive at $106.23M, providing a cushion for debt servicing and shareholder returns.